دورية أكاديمية
Histamine H4 Receptor Expression in Triple-negative Breast Cancer: An Exploratory Study.
| العنوان: | Histamine H4 Receptor Expression in Triple-negative Breast Cancer: An Exploratory Study. |
|---|---|
| المؤلفون: | Speisky D; Pathology Department., Táquez Delgado MA; British Hospital, Buenos Aires, Argentina, and Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research, School of Medical Sciences, Pontifical Catholic University of Argentina, and the National Scientific and Technical Research Council, Buenos Aires, Argentina., Iotti A; Pathology Department., Nicoud MB; British Hospital, Buenos Aires, Argentina, and Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research, School of Medical Sciences, Pontifical Catholic University of Argentina, and the National Scientific and Technical Research Council, Buenos Aires, Argentina., Ospital IA; British Hospital, Buenos Aires, Argentina, and Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research, School of Medical Sciences, Pontifical Catholic University of Argentina, and the National Scientific and Technical Research Council, Buenos Aires, Argentina., Vigovich F; Pathology Department., Dezanzo P; Pathology Department., Ernst G; Scientific Committee., Uriburu JL; Mastology Service., Medina VA; British Hospital, Buenos Aires, Argentina, and Laboratory of Tumor Biology and Inflammation, Institute for Biomedical Research, School of Medical Sciences, Pontifical Catholic University of Argentina, and the National Scientific and Technical Research Council, Buenos Aires, Argentina. |
| المصدر: | The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society [J Histochem Cytochem] 2022 Apr; Vol. 70 (4), pp. 311-322. Date of Electronic Publication: 2022 Feb 28. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: SAGE Publications Country of Publication: United States NLM ID: 9815334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1551-5044 (Electronic) Linking ISSN: 00221554 NLM ISO Abbreviation: J Histochem Cytochem Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2011->: Thousand Oaks, CA : SAGE Publications Original Publication: Baltimore : Williams & Wilkins Co., c1953- |
| مواضيع طبية MeSH: | Receptors, Histamine H4*/biosynthesis , Triple Negative Breast Neoplasms*/metabolism, Humans ; Immunohistochemistry ; Lymph Nodes/metabolism ; Prognosis |
| مستخلص: | Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype. There are neither universally accepted prognostic markers nor molecular targets related to TNBC. The histamine H4 receptor (H4R) has been characterized in TNBC experimental models, demonstrating its critical role in tumor development and progression. In this study, H4R expression was compared in breast cancer subtypes and correlated with clinical features using The Cancer Genome Atlas data (Pan-Cancer Atlas). The H4R status was further evaluated by immunohistochemistry in 30 TNBC human samples in relation to clinicopathological parameters. Results indicate that H4R was downregulated in basal-like/TNBC compared with luminal A and normal breast-like tumors. The higher expression of H4R was associated with improved progression-free and overall survival outcomes in basal-like/TNBC. H4R immunoreactivity was detected in about 70% of tumors, and its expression was positively correlated with the levels in the histologically normal peritumoral tissue. High H4R expression in peritumoral tissue correlated with reduced number of lymph node involvement and unifocal TNBC, while it was associated with increased patient survival. In conclusion, the H4R might represent a potential prognostic biomarker in TNBC. Further studies in large cohorts are needed to better understand the significance of H4R in breast cancer biology. |
| References: | Nature. 2019 May;569(7757):503-508. (PMID: 31068700) Br J Cancer. 2020 Feb;122(3):348-360. (PMID: 31748740) Cancer Biol Ther. 2006 Nov;5(11):1462-71. (PMID: 17012845) Arch Pathol Lab Med. 2010 Jun;134(6):907-22. (PMID: 20524868) Front Oncol. 2019 May 14;9:379. (PMID: 31139569) Front Pharmacol. 2019 Jun 05;10:556. (PMID: 31231212) Science. 1996 Dec 20;274(5295):2057-9. (PMID: 8953032) PLoS One. 2012;7(2):e31207. (PMID: 22363581) Clin Cancer Res. 2005 Jan 1;11(1):166-72. (PMID: 15671542) J Mol Med (Berl). 2018 Sep;96(9):951-964. (PMID: 30058054) Int J Cancer. 2008 Apr 1;122(7):1557-66. (PMID: 18058819) Cancer. 1989 Jan 1;63(1):181-7. (PMID: 2910416) Nat Commun. 2020 Jul 9;11(1):3431. (PMID: 32647202) Oncotarget. 2017 Apr 18;8(16):26471-26491. (PMID: 28460440) Breast Cancer Res Treat. 1998;52(1-3):261-88. (PMID: 10066087) Hepatology. 2011 Nov;54(5):1718-28. (PMID: 21793031) Ann Oncol. 2013 Sep;24(9):2206-23. (PMID: 23917950) Front Biosci (Elite Ed). 2011 Jun 01;3(3):1042-60. (PMID: 21622113) Cancer Biol Ther. 2008 Jan;7(1):28-35. (PMID: 17932461) Br J Pharmacol. 2020 Feb;177(3):516-538. (PMID: 30414378) CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) Breast Cancer (Dove Med Press). 2018 Nov 23;10:177-194. (PMID: 30538542) Int J Cancer. 2011 Sep 15;129(6):1310-21. (PMID: 21105047) CA Cancer J Clin. 2019 Nov;69(6):438-451. (PMID: 31577379) Eur J Cell Biol. 2008 Apr;87(4):227-36. (PMID: 18258331) Br J Cancer. 2010 Apr 13;102(8):1284-93. (PMID: 20197764) Ann Diagn Pathol. 2020 Jun;46:151507. (PMID: 32199279) Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877) Br J Pharmacol. 2010 Oct;161(4):755-67. (PMID: 20636392) Cancer. 1983 Nov 1;52(9):1551-7. (PMID: 6352003) Cell. 2018 Apr 5;173(2):400-416.e11. (PMID: 29625055) Br J Pharmacol. 2013 Sep;170(1):188-99. (PMID: 23425150) Breast. 2015 Nov;24 Suppl 2:S26-35. (PMID: 26253814) Am J Pathol. 2002 Jul;161(1):283-90. (PMID: 12107113) World J Clin Oncol. 2014 Aug 10;5(3):412-24. (PMID: 25114856) Nat Commun. 2017 Oct 20;8(1):1077. (PMID: 29057876) J Am Coll Surg. 2000 May;190(5):530-9. (PMID: 10801019) Cancer Res. 2002 Feb 15;62(4):1000-3. (PMID: 11861372) Cell. 2018 Apr 5;173(2):291-304.e6. (PMID: 29625048) Breast Cancer Res Treat. 2010 Jan;119(2):335-46. (PMID: 19266279) Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210) Comput Struct Biotechnol J. 2021 Jul 18;19:4101-4109. (PMID: 34527184) BMC Cancer. 2011 May 24;11:195:1-11. (PMID: 21609450) Breast J. 2020 Apr;26(4):739-742. (PMID: 31612573) Cell Death Dis. 2019 Oct 24;10(11):807. (PMID: 31649243) Br J Cancer. 2019 Jan;120(1):128-138. (PMID: 29988113) |
| فهرسة مساهمة: | Keywords: histamine H4 receptor; immunohistochemistry; metastasis; prognostic marker; triple-negative breast cancer |
| المشرفين على المادة: | 0 (HRH4 protein, human) 0 (Receptors, Histamine H4) |
| تواريخ الأحداث: | Date Created: 20220301 Date Completed: 20220413 Latest Revision: 20230402 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC8971688 |
| DOI: | 10.1369/00221554221083670 |
| PMID: | 35227109 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1551-5044 |
|---|---|
| DOI: | 10.1369/00221554221083670 |